The effect of a single dose of WH138 on urinary sodium excretion in adult males. -An open-label, dose-escalation study-

The effect of a single dose of WH138 on urinary sodium excretion in adult males. -An open-label, dose-escalation study- - Interventional study of WH138 on adult males

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000047118

Enrollment

Registered

2023-05-31

Start date

2022-03-18

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Adults

Interventions

Period 1 (No intake) Period 2 (WH138, Low-dose, single dose administration) Period 3 (WH138, High-dose, single dose administration)

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1) Subjects who are voluntarily giving written informed consent. 2) Adult males aged between 20 and 65 3) Subjects who can take meals, take urine samples and keep a resting state on the schedule indicated by investigators.

Exclusion criteria

Exclusion criteria: 1) Subjects who have possibilities for allergy related to the test food 2) Subjects whose clinical inspection results are estimated inappropriate to this study by principal investigator. 3) Subjects who have or had disorder in digestive, circulatory or endocrine system and who are estimated inappropriate to this study by principal investigator. 4) Subjects who are excess of daily salt intake. 5) Subjects who are estimated inappropriate to participate to this study by principal investigator.

Design outcomes

Primary

Measure	Time frame
Urinary sodium excretion and urine volume Urinary WH138 excretion	—

Countries

Japan

Contacts

Public ContactAyuko Oyama

Otsuka Pharmaceutical Co., Ltd Saga Nutraceuticals Research Institute

Oyama.Ayuko@otsuka.jp0952-52-1522

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026